Literature DB >> 7286784

Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis.

J Neuberger, G Mieli-Vergani, J M Tredger, M Davis, R Williams.   

Abstract

Previous investigations have shown that patients with fulminant hepatic failure after halothane anaesthesia have a circulating antibody which reacts with an antigen present on the surface of halothane-altered hepatocytes. In the present study, it has been shown that the expression of the antigen is associated with the oxidative metabolism of halothane, in contrast with results of other groups which have shown that the reductive route is involved in the direct hepatotoxic reaction attributed to halothane.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286784      PMCID: PMC1420052          DOI: 10.1136/gut.22.8.669

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

Review 1.  Antigens of the human liver.

Authors:  I G McFarlane; B M Wojcicka; R Williams
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

2.  Halothane hepatotoxicity: enhancement by polychlorinated biphenyl pretreatment.

Authors:  E S Reynolds; M T Moslen
Journal:  Anesthesiology       Date:  1977-07       Impact factor: 7.892

3.  Hypoxia and halothane metabolism in vivo: release of inorganic fluoride and halothane metabolite binding to cellular constituents.

Authors:  L A Widger; A J Gandolfi; R A Van Dyke
Journal:  Anesthesiology       Date:  1976-03       Impact factor: 7.892

4.  Unexplained hepatitis following halothane.

Authors:  B Walton; B R Simpson; L Strunin; D Doniach; J Perrin; A J Appleyard
Journal:  Br Med J       Date:  1976-05-15

5.  An animal model of hepatotoxicity associated with halothane anesthesia.

Authors:  I G Sipes; B R Brown
Journal:  Anesthesiology       Date:  1976-12       Impact factor: 7.892

6.  Hepatotoxicity and halothane metabolism in an animal model with application for human toxicity.

Authors:  M J Cousins; J H Sharp; G K Gourlay; J F Adams; W D Haynes; R Whitehead
Journal:  Anaesth Intensive Care       Date:  1979-02       Impact factor: 1.669

7.  Sensitisation to halothane-altered liver components in severe hepatic necrosis after halothane anaesthesia.

Authors:  D Vergani; D Tsantoulas; A L Eddleston; M Davis; R Williams
Journal:  Lancet       Date:  1978-10-14       Impact factor: 79.321

8.  Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium.

Authors:  J Trowell; R Peto; A C Smith
Journal:  Lancet       Date:  1975-04-12       Impact factor: 79.321

9.  Controlled prospective study of the effect on liver function of multiple exposures to halothane.

Authors:  R Wright; O E Eade; M Chisholm; M Hawksley; B Lloyd; T M Moles; J C Edwards; M J GArdner
Journal:  Lancet       Date:  1975-04-12       Impact factor: 79.321

10.  Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis.

Authors:  D Vergani; G Mieli-Vergani; A Alberti; J Neuberger; A L Eddleston; M Davis; R Williams
Journal:  N Engl J Med       Date:  1980-07-10       Impact factor: 91.245

View more
  22 in total

Review 1.  Occupational exposure to volatile anaesthetics: epidemiology and approaches to reducing the problem.

Authors:  C Byhahn; H J Wilke; K Westpphal
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

Review 3.  Drug metabolism and hepatotoxicity.

Authors:  J M Tredger; M Davis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  The immunological basis of adverse drug reactions. A report on a symposium held in Liverpool on 6th April 1988.

Authors:  B K Park; J W Coleman
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

5.  A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis.

Authors:  J C Homberg; C Andre; N Abuaf
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

6.  Trifluoroacetylated IgG4 antibodies in a child with idiosyncratic acute liver failure after first exposure to halothane.

Authors:  Christine Nguyen; Noel R Rose; Dolores B Njoku
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-08       Impact factor: 2.839

7.  Characterization of a halothane-induced humoral immune response in rabbits.

Authors:  A H Callis; S D Brooks; T P Roth; A J Gandolfi; B R Brown
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

8.  Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury.

Authors:  Dolores B Njoku; Zhaoxia Li; Nicole D Washington; Jenelle L Mellerson; Monica V Talor; Rajni Sharma; Noel R Rose
Journal:  Eur J Immunol       Date:  2009-06       Impact factor: 5.532

9.  Anti-LSP antibodies in acute liver disease.

Authors:  R Meliconi; A Perperas; D Jensen; A Alberti; I G McFarlane; A L Eddleston; R Williams
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

10.  Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug.

Authors:  P Beaune; P M Dansette; D Mansuy; L Kiffel; M Finck; C Amar; J P Leroux; J C Homberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.